Autres langues ImmuPharma plc

Actions

IMM

GB0033711010

Marché Fermé - London S.E. Autres places de cotation 17:35:05 03/07/2024			Varia. 5j.	Varia. 1 janv.
2,085 ^GBX	-2,57%		-2,80%	+25,07%

05/06	ImmuPharma plc publie ses résultats pour l'exercice clos le 31 décembre 2023	CI
29/04	Immunovia annonce la nomination de Lisa Fordas au poste de directrice du laboratoire clinique	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

ImmuPharma : 2024 Result of Annual General Meeting – all resolutions passed	01/07
EARNINGS AND TRADING: STV sees advertising upturn; Angle loss narrows	05/06
ImmuPharma : Annual Report 2023	05/06
ImmuPharma : FINAL RESULTS for the twelve months ended 31 December 2023	05/06
ImmuPharma plc Reports Earnings Results for the Full Year Ended December 31, 2023	05/06
Immunovia Announces the Appointment of Lisa Fordas as Clinical Laboratory Director	29/04
Immupharma jumps amid new IP strategy for P140 technology platform	02/04
ImmuPharma plc Initiates New Intellectual Property Strategy to Significantly Enhance the Patent Life and Commercial Value for Its P140 Technology Platform	02/04
ImmuPharma : Incanthera Provides Commercial Update and Revenue Forecasts	26/03
Incanthera says first order from skincare deal doubles	25/03
Stocks make tepid start to new week	25/03
AIM WINNERS & LOSERS: ImmuPharma order doubles; Aeorema swings to loss	25/03
ImmuPharma CEO Tim McCarthy discusses financial stability and promising drug developments	08/03
EARNINGS AND TRADING: Challenger signs farm-out; Ricardo revenue up	06/03
TR1 – Major Holding by Lanstead (Date: 28 December 2023)	02/01
ImmuPharma : TR1 – Major holding by Lanstead	20/12
EARNINGS AND TRADING: Time Finance revenue up; Libertine loss narrows	19/12
Immupharma Decides to Move Directly to Late-stage Trial of Lupus Therapy	19/12
ImmuPharma Appoints Contract Research Organization for Late-stage Lupuzor Trial	19/12
Immupharma plc Announces Key Updates on Its Late Stage P140 Program, in Patients with Systemic Lupuzortm	19/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues ImmuPharma plc

Actions

IMM

GB0033711010

Autres langues

Filtres